Genesystem Co., Ltd. (KOSDAQ:363250)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,130.00
+145.00 (2.91%)
At close: May 8, 2026
Market Cap41.43B -45.4%
Revenue (ttm)381.36M -68.4%
Net Income-11.96B
EPS-1,754.00
Shares Out8.29M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume38,050
Average Volume44,338
Open4,985.00
Previous Close4,985.00
Day's Range4,970.00 - 5,300.00
52-Week Range3,480.00 - 10,690.00
Beta0.16
RSI33.09
Earnings DateMar 27, 2026

About Genesystem

Genesystem Co., Ltd., a biotech engineering company, specializes in molecular testing solutions to target on-site testing needs. The company offers PCR systems, multiplex biochips, and PCR reagents. It also provides human pathogen assays, including novel coronavirus (SARS-CoV-2) detection kits, SARS-CoV-2/Flu/RSV simultaneous detection kits, and mycobacterium tuberculosis detection kits; veterinary diagnostics; food safety assays comprising foodborne pathogen detection kits, HALAL food testing kits, and meat species identification kits; and nuc... [Read more]

Industry Electromedical and Electrotherapeutic Apparatus
Founded 2010
Employees 54
Stock Exchange KOSDAQ
Ticker Symbol 363250
Full Company Profile

Financial Performance

In 2025, Genesystem's revenue was 381.36 million, a decrease of -68.42% compared to the previous year's 1.21 billion. Losses were -11.96 billion, 34.1% more than in 2024.

Financial Statements